News
PRTA
17.40
+0.23%
0.04
Expert Ratings For Prothena Corp
Benzinga · 3h ago
Prothena Price Target Maintained With a $84.00/Share by HC Wainwright & Co.
Dow Jones · 4h ago
HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $84 Price Target
Benzinga · 4h ago
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
NASDAQ · 6h ago
RBC Capital Keeps Their Hold Rating on Prothena (PRTA)
TipRanks · 7h ago
Prothena’s Promising Therapeutic Developments and Positive Trial Outcomes Justify Buy Rating
TipRanks · 7h ago
Prothena’s Strategic Advancements and Financial Strength Underpin Buy Rating
TipRanks · 13h ago
Prothena Corporation Reports Q3 2024 Financial Results
TipRanks · 15h ago
Form 10-Q – QUARTERLY REPORT" This is a quarterly financial report filed by Prothena Corporation Public Limited Company with the United States Securities and Exchange Commission (SEC).
Press release · 17h ago
Prothena Continues To Expect 2024 Net Cash Used In Operating And Investing Actives To Be $148M - $160M And Expects To End Year With $468M (Midpoint) In Cash, Cash Equivalents And Restricted Cash
Benzinga · 21h ago
Prothena reports Q3 EPS ($1.10), consensus ($1.18)
TipRanks · 21h ago
Here are the major earnings after the close today
Seeking Alpha · 1d ago
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
NASDAQ · 2d ago
Earnings Preview For Prothena Corp
Benzinga · 2d ago
Weekly Report: what happened at PRTA last week (1104-1108)?
Weekly Report · 2d ago
Weekly Report: what happened at PRTA last week (1028-1101)?
Weekly Report · 11/04 09:17
Prothena (PRTA) Gets a Buy from Oppenheimer
TipRanks · 10/29 11:46
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
NASDAQ · 10/29 08:48
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Benzinga · 10/28 14:14
Weekly Report: what happened at PRTA last week (1021-1025)?
Weekly Report · 10/28 09:15
More
Webull provides a variety of real-time PRTA stock news. You can receive the latest news about Prothena through multiple platforms. This information may help you make smarter investment decisions.
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.